This week in psychedelic business news: Enveric Biosciences uses AI to identify viable psychedelic drug candidates; Novamind launches end-of-life palliative care program; and PharmaTher tests ketamine to treat Parkinson’s Disease.
In this episode of the Psychedelic Spotlight podcast, we spotlight Evan Levine, Chairman & CEO of PsyBio Therapeutics, an intellectual property driven biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health issues and other disorders.
“A mushroom is not a pharmaceutical product,” CEO Evan Levine stresses, and explains why his company’s method of biologically engineering psilocybin is “cheaper, faster, greener.”
The OTCQB is a middle-tier market for entrepreneurial and development stage American and international companies.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.